Intravenous High Dose NAC and Sodium Bicarbonate for the Prevention of Contrast-induced Acute Injury
NCT01612013 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 500
Last updated 2012-06-05
Summary
Contrast-induced acute kidney injury is a common cause of acquired in-hospital renal insufficiency and is associated with prolonged hospitalization and unfavorable early and late outcomes. The investigators sought to compare 4 different strategies (intravenous high-dose of N-acetylcysteine, sodium bicarbonate, the combination of both, and saline alone) in the prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography using high-osmolar contrast media defined by creatinine and cystatin C serum levels.
Conditions
- Acute Renal Failure
Interventions
- DRUG
-
Sodium bicarbonate plus saline
Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
- DRUG
-
Intravenous NAC plus saline
Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure and followed by 50 mg/kg in 500 ml dextrose 5% during the contrast exposure and for 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
- DRUG
-
NAC plus sodium bicarbonate plus saline
Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during the contrast exposure and for 6 hours after the procedure. Sodium bicarbonate solution(150 mEq of sodium) was began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
- DRUG
-
Saline
Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
- DRUG
-
NAC plus saline
Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
- DRUG
-
NAC plus sodium bicarbonate plus saline
Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
Sponsors & Collaborators
-
Hospital das Forças Armadas, Brazil
collaborator OTHER -
InCor Heart Institute
collaborator OTHER -
Federal University of São Paulo
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2005-05-31
- Primary Completion
- 2009-05-31
- Completion
- 2009-12-31
Countries
- Brazil
Study Locations
More Related Trials
-
COmbined N-acetylcysteine and Bicarbonate in PCI To Reduce Adverse Side Effect of contrasT
NCT00497328 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Prevention of Contrast Nephropathy by Sodium Bicarbonate Versus Sodium Chloride and N-acetylcysteine
NCT00353340 ·Status: COMPLETED ·Phase: NA
-
Sodium Bicarbonate Versus Saline for the Prevention of Contrast-induced Nephropathy
NCT00606827 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Trial of Sodium Bicarbonate to Prevent Contrast-Induced Nephropathy
NCT00424320 ·Status: UNKNOWN ·Phase: PHASE3
-
NAC, NaHCO3 and NS Prophylaxis for CTPA in the ED on Suspicion of PE: A Randomized Controlled Trial
NCT02483143 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure
NCT00716001 ·Status: UNKNOWN ·Phase: PHASE4
-
Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate
NCT00472563 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Prevention of Acute Kidney Injury by N-Acetylcystein in Patients Undergone Cardiac Valve Replacement
NCT03440268 ·Status: UNKNOWN ·Phase: PHASE4
-
PROVOCATION Trial - PROphylactic intraVenOus Hydration for Contrast Agent Toxicity PreventION
NCT00130598 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Bicarbonate v Saline to Prevent Contrast Nephropathy
NCT00384995 ·Status: TERMINATED ·Phase: PHASE4
-
The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy
NCT03627130 ·Status: COMPLETED ·Phase: PHASE2
-
A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate
NCT00579995 ·Status: TERMINATED ·Phase: NA
-
N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
NCT00780962 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Intravenous N-acetylcysteine to Prevent Contrast Media Induced Nephrotoxicity in an Emergency Center
NCT01467154 ·Status: COMPLETED
-
Preventing Contrast Nephropathy With Sodium Bicarbonate in Patients With Pulmonary Edema,Heart Failure,Uncontrolled HTN
NCT00513825 ·Status: COMPLETED ·Phase: PHASE2
-
Preventing Contrast-induced Nephropathy: Evaluating Hydration Strategies and L-carnitine Administration
NCT01786824 ·Status: TERMINATED ·Phase: PHASE3
-
Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy
NCT01093131 ·Status: WITHDRAWN ·Phase: PHASE4
-
Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate
NCT00540904 ·Status: COMPLETED ·Phase: PHASE2
-
Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury
NCT07016074 ·Status: RECRUITING ·Phase: PHASE2
-
The Acetylcysteine for Contrast-Induced Nephropathy Trial
NCT00736866 ·Status: COMPLETED ·Phase: PHASE3
-
Prevention of Serious Adverse Events Following Angiography
NCT01467466 ·Status: COMPLETED ·Phase: PHASE3
-
Contrast Nephropathy Prevention With N-Acetylcysteine in Acute Myocardial Infarction
NCT00237614 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Does Bicarbonate in Addition to Theophylline Reduce CIN?
NCT02643602 ·Status: COMPLETED ·Phase: NA
-
The Use of Sodium Bicarbonate in the Prevention of Contrast Induced Nephropathy
NCT00494637 ·Status: TERMINATED ·Phase: NA
-
N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography
NCT00830193 ·Status: COMPLETED ·Phase: PHASE2/PHASE3